Tigecycline's Patent Extensions
Tigecycline, sold as Tygacil by Wyeth (now Pfizer), treats complicated skin infections and intra-abdominal infections. Its original patents expired around 2015-2020, but Pfizer secured pediatric exclusivity extensions, pushing full generic entry to May 2025 in the US.[1] This delays ANDA approvals under Hatch-Waxman, blocking FDA tentative approvals for generics until exclusivity lapses.
Timeline for Generic Entry
- Core patent expiry: US Patent 7,485,741 (key formulation) expired December 2020.
- Pediatric exclusivity: Added 6 months in 2021, extending market protection to May 30, 2025.[1]
- Litigation status: No major ongoing Paragraph IV challenges reported; earlier suits settled, aligning entry with exclusivity end.[2]
Generics from Mylan (now Viatris) and others await this date, with FDA listing 5 tentative approvals pending exclusivity.
Direct Impact on Generic Competition
The extension blocks generics for ~4-5 extra years post-patent expiry, preserving Pfizer's monopoly pricing. US sales peaked at $300M+ annually pre-generic pressure; exclusivity maintains ~$200M yearly revenue through 2025.[3] It limits immediate price drops—generics typically cut costs 80-90% upon entry.
Why Pediatric Exclusivity Delays Competition More Than Patents
Unlike patents (challengeable via ANDA Paragraph IV, gaining 30-month stays), pediatric extensions are non-challengeable FDA grants for completing pediatric studies. Tigecycline's extension stemmed from trials in kids with complicated infections, automatically tacking 6 months onto all exclusivities without litigation risk.[4]
Generic Makers Waiting in Line
| Company | Status | Target Entry |
|---------|--------|--------------|
| Viatris (Mylan) | Tentative ANDA approved | Post-May 2025 [1] |
| Apotex | Filed ANDA | Post-May 2025 [2] |
| Fresenius Kabi | Filed ANDA | Post-May 2025 [1] |
No 180-day exclusivity for first filer due to no Paragraph IV certification against the pediatric period.
Market Effects and Pricing Pressure
Post-2025, expect 3-5 generics, dropping WAC from ~$2,000/vial (branded) to $200-400.[3] Global impact varies: EU generics entered earlier (2014); India/China have locals already. Hospital formulary switches will accelerate post-entry, hitting Pfizer volumes 70-90% in year 1.
Biosimilar or Alternative Competition Risks
No biosimilars (tigecycline is small-molecule). Competitors like meropenem or ceftazidime-avibactam erode share but don't fully substitute. Exclusivity shields against these until 2025, though resistance trends boost tigecycline demand.
When Does Protection Fully End?
May 30, 2025 (US pediatric expiry). Check DrugPatentWatch.com for updates on settlements or new Orange Book listings: DrugPatentWatch - Tygacil.[1]
Sources
[1]: DrugPatentWatch.com - Tygacil Patent Timeline
[2]: FDA Orange Book - Tigecycline Entries
[3]: IQVIA Sales Data via Evaluate Pharma
[4]: FDA Pediatric Exclusivity Guidance